Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?

Dialogues in Clinical Neuroscience

Volumn 5, Issue 1, 2003, Pages 7-15

  Ravona Springer, Ramit ^a   Davidson, Michael ^a,b   Noy, Shlomo ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cardiovascular risk factor; Cholesterol; Diabetes; Hyperhomocysteinemia; Vascular dementia

Indexed keywords

ALZHEIMER DISEASE; AUTOPSY; CARDIOVASCULAR RISK; CLINICAL FEATURE; DEMENTIA; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; HUMAN; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; REVIEW; RISK FACTOR;

EID: 0037741460     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11:205-242.
2. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet. 1974;2:207-209.
3. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632-637.
4. Perry E, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ. 1978;2:1457-1459.
5. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol. 1978;4:273-277.
6. Bartus RT, Emerich DF. Cholinergic markers in Alzheimer disease. JAMA. 1999;282:2208-2209.
7. Lin L, Georgievska B, Mattsson A, Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci U S A. 1999;96:12108-12113.
8. Isacson O, Lin L. Cholinergic modulation of amyloid processing and dementia in animal models of Alzheimer's disease. Ann N Y Acad Sci. 2000;920:309-314.
9. McKahnn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
10. Fisher CM. Dementia in.cerebrovascular disease. In: Toole JF, Siekert RG, Whisnant JP, eds. Cerebral Vascular Disease: Sixth Conference. New York, NY: Grune-Stratton; 1968:232-236.
11. Deutsch JA. The cholinergic synapse and the site of memory. Science. 1971;174:788-794.
12. Collerton D. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience. 1986;19:1-28.
13. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci. 1977;34:247-265.
14. Babikian V, Ropper AH. Binswanger's disease: a review. Stroke. 1987;18:2-12.
15. Erkinjuntti T. Types of multi-infarct dementia. Acta Neurol Scand. 1987;75:391-399.
16. Roman GC. Senile dementia of the Binswanger type: a vascular form of dementia in the elderly. JAMA. 1987;258:1782-1788.
17. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the state of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992;42:473-480.
18. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260.
19. Skoog I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother. 1997;51:367-375.
20. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
21. Pantoni L. Pathophysiology of age-related cerebral white matter changes. Cerebrovasc Dis. 2002;13(suppl 2):7-10.
22. Englund E. Neuropathology of white matter lesions in vascular cognitive impairment. Cerebrovasc Dis. 2002;13(suppl 2):11-15.
23. Schmidt R, Schmidt H, Kapeller P, Lechner A, Fazekas F. Evolution of white matter lesions. Cerebrovasc Dis. 2002;13(suppl 2):16-20.
24. Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach M. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease? Stroke. 2002;33:1981-1985.
25. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813-817.
26. Henon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D. Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology. 2001;57:1216-1222.
27. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S115-S123.
28. Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000;21:321-330.
29. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia. 1996;39:1392-1397.
30. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiological study. Neurobiol Aging. 2000;21:153-160.
31. Bots ML, van Kooten F, Haverkate F, et al. Coagulation and fibrinolysis markers and risk of dementia: the Dutch vascular factors in dementia study. Haemostasis. 1998;28:216-222.
32. Kalmijn S, Launer LJ, Lindemans J, Bots JL, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol. 1999;150:283-289.
33. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. A trial fibrillation and dementia in a population-based study: the Rotterdam Study. Stroke. 1997;28:316-321.
34. Graves AB, van Duijn CM, Chandra V, et al, for the EURODEM Risk Factors Research Group. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-controlled studies. Int Epidemiol. 1991;20:S48-S57.
35. Ott A, Breteler MM, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia association with education: the Rotterdam Study. BMJ. 1995;310:970-973.
36. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 1997;349:151-154.
37. Breteler MM, Bots ML, Ott A, Hofman A. Risk factors for vascular disease and dementia. Haemostasis. 1998;28:167-173.
38. Kivipelto M, Helkala EL, Hanninen T, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population-based study. BMJ. 2001;322:1447-1451.
39. Tyas SL, Manfreda J, Strain LA, Montgomery PR. Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol. 2001;30:590-597.
40. Kalmijn S. Dietary fat intake and risk of incident dementia in the Rotterdam Study. Ann Neurol. 1997;42:776-782.
41. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 1998;17:14-20.
42. Diaz-Arrastia R. Hyperhomocysteinemia: a new risk factor for Alzheimer's disease? Arch Neurol. 1998;55:1-2.
43. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283-1290.
44. Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev. 2002;18(suppl 3):S21-S26.
45. Meigs JB. Epidemiology of the metabolic syndrome. 2002. Am J Manag Care. 2002;8(suppl):S283-S292. Quiz S293-S296.
46. Holmes C, Cairns N, Lantos P, et al. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry. 1999;174:45-50.
47. Neuropathology Group of the Medical Research Council Cognitive Function and Aged Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169-175.
48. Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002;50:1431.
49. Moroney JT, Bagiella E, Desmond DW, et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997;49:1096-1105.
50. Swan GE, LaRue A, Carmelli D, Reed TE, Fabsitz RR. Decline in cognitive performance in aging twins. Heritability and biobehavioral predictors from the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol. 1992;49:476-481.
51. Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology. 2001;57:1447-1452.
52. Bonarek M, Barberger GP, Letenneur L, Deschamps V, Dubroka B, Datrigues JF. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology. 2000;19:141-148.
53. Kabara JJ. A critical review of brain cholesterol metabolism. Prog Brain Res. 1973;40:363-382.
54. Morell P, Jurevics H. Origin of cholesterol in myelin. Neurochem Res. 1996;21:463-470.
55. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol. 2001;12:105-112.
56. Roheim PS, Carey M, Forte T, Vega GL. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A. 1979;76:4646-4649.
57. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-631.
58. Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer's disease. Is there a link? Neurology. 2001;57:1089-1093.
59. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of amyloid in hippocampal neurons. Proc Natl Acad Sci U S A. 1998;95:6460-6464.
60. Frears E, Stephens D, Walters C, Davies H, Austen B. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 1999;10:1699-1705.
61. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effects on the alpha-secretase ADAM 10. Proc Natl Acad Sci U S A. 2001;98:5815-5820.
62. Wolozin B, Kellman W, Rousseau P, Celesia CC, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
63. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
64. Crisby M, Carlson LA, Winblan B. Statins in the prevention and treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16:131-136.
65. Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci. 2001;187:81-89.
66. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
67. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487-495.
68. Chapman J, Korczyn A, Karussis DM, Michaelson DM. The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology. 2001;57:1482-1485.
69. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994;17:525-530.
70. Prince M, Lovestone S, Cervilla J, et al. The association between APOE and dementia does not seem to be mediated by vascular factors. Neurology. 2000;54:397-402.
71. Haraki T, Takegoshi T, Kitoh C, et al. Carotid artery intima-media thickness and brachial artery flow-mediated vasodilation in asymptomatic Japanese male subjects amongst apolipoprotein E phenotypes. J Intern Med. 2002;252:114-120.
72. Djousse L, Myers RH, Province MA, et al. Influence of apolipoprotein E, smoking, and alcohol intake on carotid atherosclerosis: National Heart, Lung, and Blood Institute Family Heart Study. Stroke. 2002;33:1357-1361.
73. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358:115-119.
74. Lambert JC, Brousseau T, Defosse V, et al. Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations: the ECTIM study. Hum Mol Genet. 2000;9:57-61.
75. Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis. 2001;154:529-537.
76. Scuteri A, Bos AJ, Zonderman AB, Brant LJ, Lakatta EG, Fleg JL. Is the apoE4 allele an independent predictor of coronary events? Am J Med. 2001;110:28-32.
77. Slooter AJ, Tang MX, van Duijn CM, et al. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA. 1997;277:818-821.
78. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol. 1996;148:2083-2095.
79. Jarrett RJ. Epidemiology and public health aspects of non-insulin-dependent diabetes mellitus. Epidemiol Rev. 1989;11:151-171.
80. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia. 1995;38:1061-1068.
81. Skoog I. Risk factors for vascular dementia: a review. Dementia. 1994;5:137-144.
82. Tatemichi TK, Desmond DW, Paik M, et al. Clinical determinants of dementia related to stroke. Ann Neurol. 1993;33:568-575.
83. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635-641.
84. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. The Honolulu-Asia Aging Study. Diabetes. 2002;51:1256-1262.
85. Landin K, Blennow K, Wallin A, Gottfries CG. Low blood pressure and blood glucose levels in Alzheimer's disease. Evidence for a hypometabolic disorder? J Intern Med. 1993;233:357-363.
86. Nielson KA, Nolan JH, Berchtold NC, Sandman CA, Mulnard RA, Cotman CW. Apolipoprotein-E genotype of diabetic dementia patients: is diabetes rare in Alzheimer's disease? J Am Geriatr Soc. 1996;44:897-904.
87. Vanhanen M, Kuusisto J, Koivisto K, et al. Type 2 diabetes and cognitive function in a non-demented population. Acta Neurol Scand. 1999;100:97-101.
88. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology. 1999;52:971-975.
89. Munch G, Mayer S, Michaelis J, et al. Influence of advanced glycation endproducts and AGE inhibitors on nucleation-dependent polymerization of beta-amyloid peptide. Biochim Biophys Acta. 1997;1360:17-29.
90. Dickson DW, Sinicropi S, Yen SH, et al. Glycation and microglial reaction in lesions of Alzheimer's disease. Neurobiol Aging. 1996;17:733-733.
91. Mukherjee A, Song E, Kihiko-Ehmann M, et al. Insulin hydrolyzes amyloid peptides to products that are neither neurotoxic nor deposit on amyloid plaques. J Neurosci. 2000;20:8745-8749.
92. Qiao Qiu W, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J Biol Chem. 1998;273:32730-32738.
93. Stolk RP, Breteler MM, Ott A, et al. Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care. 1997;20:792-795.
94. Craft S, Dagogo-Jack SE, Wiethop BV, et al. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci. 1993;107:926-940.
95. Palovcik RA, Phillips MI, Kappy MS, Raizada MK. Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res. 1984;309:187-191.
96. Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging. 1996;17:123-130.
97. Unger J, McNeill TH, Moxley RT, White M, Moss A, Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience. 1989;31:143-157.
98. Petrovich H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS, Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21:57-62.
99. Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta Neuropathol (Berl). 1984;62:178-184.
100. Johansson BB. Pathogenesis of vascular dementia: the possible role of hypertension. Dementia. 1994;5:174-176.
101. Wallin A, Sjogren M, Edman A, Blennow K, Regland B. Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol. 2000;44:229-235.
102. Wallin A. The overlap between Alzheimer's disease and vascular dementia: the role of white matter changes. Dement Geriatr Cogn Disord. 1998;9(suppl 1):30-35.
103. Launer LJ, Masaki K, Petrovich H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851.
104. Peila R, White LR, Petrovich H, et al. Joint effect of the APOE gene and midlife systolic blood pressure on late life cognitive impairment. The Honolulu Asia Aging Study. Stroke. 2001;32:2882-2889.
105. Carmelli D, Swan GE, Reed T, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology. 1998;50:1580-1585.
106. Elias MF, Wolf PA, D'Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham study. Am J Epidemiol. 1993;138:353-364.
107. Skoog I. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141-1145.
108. Swan GE, LaRue A, Carmelli D, Reed TE, Fabsitz RR. Decline in cognitive performance in aging twins. Heritability and biobehavioral predictors from the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol. 1992;49:476-481.
109. Clare Morris M. Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol. 2001;58:1640-1646.
110. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31:780-786.
111. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D. Cerebrovascular disease, the ApoE4 allele and cognitive decline in a community-based study of elderly men. Stroke, 1996;27:2230-2235.
112. Swain RA, St Clair L. The role of folic acid in deficiency states and prevention of disease. J Fam Pract. 1997;44:138-144.
113. Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol. 1998;18:429-440.
114. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55:578-592.
115. Leblhuber F, Walli J, Artner-Dworzak E, et al. Hyperhomocysteinemia in dementia. J Neural Transm. 2000;107:1469-1474.
116. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
117. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol. 2002;51:285-289.
118. De Groot JC, De Leeuw FE, Oudkerk M, et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol. 2002;52:335-341.
119. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A. 1997;94:S923-S928.
120. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000;20:6920-6926.
121. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci. 2002;22:1752-1762.
122. Cheng A, Braunstein JB, Dennison C, Nass C, Blumenthal RS. Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy. Clin Cardiol. 2002;25:205-212.
123. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med. 2000;343:16-22.
124. Platz EA, Willet WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control. 2000;11:579-588.
125. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156:445-453.
126. Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol. 2001;58:498-504.
127. Friedland RP, Fritsch T, Smyth KA, et al. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc Natl Acad Sci U S A. 2001;98:3440-3445.
128. Ruitenberg A, van Swieten JC, Witteman JC, et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet. 2002;359:281-286.